Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
End-of-day quote. End-of-day quote Shanghai Stock Exchange - 06/18
140 CNY   +2.94%
06/16China stocks fall as Sino-West tensions hit risk appetite
RE
06/02China's Stemirna raises about $200 million to fund COVID-19 vaccine development
RE
05/14WUXI APPTEC  : Articles of association
PU
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/11/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
146.02 143.96 136 136 140 Last
20645880 29846420 33548830 21719610 22954590 Volume
-2.52% -1.41% -5.53% 0.00% +2.94% Change
Financials
Sales 2021 22 153 M 3 433 M 3 433 M
Net income 2021 4 189 M 649 M 649 M
Net cash position 2021 9 335 M 1 447 M 1 447 M
P/E ratio 2021 99,8x
Yield 2021 0,26%
Sales 2022 28 830 M 4 468 M 4 468 M
Net income 2022 5 385 M 835 M 835 M
Net cash position 2022 9 168 M 1 421 M 1 421 M
P/E ratio 2022 76,0x
Yield 2022 0,35%
Capitalization 412 B 63 775 M 63 781 M
EV / Sales 2021 18,2x
EV / Sales 2022 14,0x
Nbr of Employees 27 272
Free-Float 54,1%
More Financials
Company
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (65,7%): small molecules discovery services, bioanalytical services, medical devices safety testing... 
Read more
More about the company
Ratings of WuXi AppTec Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about WUXI APPTEC CO., LTD.
06/16China stocks fall as Sino-West tensions hit risk appetite
RE
06/02China's Stemirna raises about $200 million to fund COVID-19 vaccine developme..
RE
05/14WUXI APPTEC  : Articles of association
PU
05/14WUXI APPTEC  : (1) poll results of the 2020 annual general meeting, the first a ..
PU
05/07WUXI APPTEC  : Unlocking and trading of the initial grant of restricted a shares..
PU
04/30WUXI APPTEC  : Profit Soars 395% in First Quarter on Robust Demand for Pharmaceu..
MT
04/29WuXi AppTec First-Quarter Net Profit Jumped as Investment Income Increased
DJ
04/29WUXI APPTEC  : End of lock-up period of restricted a shares under the a share ip..
PU
04/28WUXI APPTEC  : Fulfillment of vesting conditions for first vesting period of fir..
PU
04/28WUXI APPTEC  : Cancellation of part of the share options granted under the 2019 ..
PU
04/28WUXI APPTEC  : Unlocking and trading of the reserved grant of restricted a share..
PU
04/22China's Wuxi City Hosts Healthcare Conference Amid Efforts to Boost Biomedica..
MT
04/08WUXI APPTEC  : Form of proxy for the first H Share class meeting
PU
04/08WUXI APPTEC  : Notice of the first H Share class meeting for 2021
PU
04/08WUXI APPTEC  : Form of proxy for the Annual General Meeting
PU
More news
News in other languages on WUXI APPTEC CO., LTD.
2018Hong Kong parti pour être en tête du classement des IPO en 2018
2018Fosun Tourism (Club Med) lève 428 millions de dollars lors de son IPO à Hong ..
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
More recommendations
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 165,16 CNY
Last Close Price 140,00 CNY
Spread / Highest target 44,8%
Spread / Average Target 18,0%
Spread / Lowest Target -9,23%
EPS Revisions
Managers and Directors
NameTitle
Ge Li Chairman, President & Co-Chief Executive Officer
Qing Yang Co-CEO, Executive Director & Executive VP
Ellis Chu Chief Financial Officer & Senior Vice President
Harry He Chairman-Supervisory Board
Frederick H. Hausheer Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.24.70%63 775
GILEAD SCIENCES, INC.14.33%83 541
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784